Celgene Targets Blood Cancers with Major Buys [News in Brief]

Lenalidomide maker diversifies its CAR T portfolio and acquires a near-market JAK inhibitor with Juno, Impact deals.

from Cancer via ola Kala on Inoreader http://ift.tt/2ElxrH9
via IFTTT